These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3463436)

  • 21. Mathematical model for adriamycin (doxorubicin) pharmacokinetics.
    Reich SD; Steinberg F; Bachur NR; Riggs CE; Goebel R; Berman M
    Cancer Chemother Pharmacol; 1979; 3(2):125-31. PubMed ID: 509697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
    Jones WG; Mattsson W
    Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
    Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
    Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic analysis of adriamycin (doxorubicin) and related fluorescent compounds in Ehrlich tumor-bearing mouse plasma and tissues.
    Shinozawa S; Fukuda T; Araki Y; Oda T
    Acta Med Okayama; 1982 Apr; 36(2):125-32. PubMed ID: 7136849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
    Cersosimo RJ; Hong WK
    J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of 4'-epi-doxorubicin in man.
    Weenen H; Lankelma J; Penders PG; McVie JG; ten Bokkel Huinink WW; de Planque MM; Pinedo HM
    Invest New Drugs; 1983; 1(1):59-64. PubMed ID: 6590528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A phase II study of epirubicin in advanced lung cancer].
    Furuse K; Fukuoka M; Yamamoto M; Kawahara M; Tsuruta M; Kodama N; Arai R; Hayashi S; Kiyota M; Kubota K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2835-40. PubMed ID: 3019252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fundamental studies on intravesical instillation of 4'-epi-adriamycin for the treatment of bladder cancer].
    Tsushima T
    Hinyokika Kiyo; 1985 Nov; 31(11):1945-56. PubMed ID: 3867286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration.
    Strocchi E; Camaggi CM; Rossi AP; Angelelli B; Comparsi R; Franchini A; Del Prete P; Cola B; Pannuti F
    Drugs Exp Clin Res; 1985; 11(4):295-301. PubMed ID: 3013561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.
    Chlebowski RT; Chan KK; Tong MJ; Weiner JM; Ryden VM; Bateman JR
    Cancer; 1981 Sep; 48(5):1088-95. PubMed ID: 6268277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacokinetic studies on THP-ADM (tetrahydropyranyl adriamycin)].
    Majima H
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):865-70. PubMed ID: 3566297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
    Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
    Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
    Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats.
    Lee HJ; Paik WH; Lee MG
    Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):195-204. PubMed ID: 8832911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Høst H
    Eur J Cancer; 1990 Jan; 26(1):45-8. PubMed ID: 2138477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative studies on the pharmacokinetics between THP and adriamycin in the same patients].
    Nakajima O; Imamura Y; Matsumoto A; Koyama Y; Shomura T; Kawamura K; Murata S
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):261-70. PubMed ID: 3947106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intra-arterial infusion of adriamycin in the treatment of locally advanced breast cancer].
    Yayoi E; Inaji H; Maeura Y; Mori T; Takatsuka Y
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2751-9. PubMed ID: 6508325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.